SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("GoodRx†or the "Company†), the leading platform for medication savings in the U.S., today announced that executives from the Company will participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 13, 2026 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during which GoodRx will discuss business updates. A live webcast will be available on the Company's Invest ...

Core Insights - GoodRx has announced the availability of Repatha® (evolocumab) at a significantly reduced cash price, making it more accessible to patients [1] - The new price for Repatha is set at $239, which represents a nearly 60% discount off the retail pharmacy list price [1] Company Overview - GoodRx is positioned as the leading platform for medication savings in the U.S., focusing on improving affordability in healthcare [1] Industry Impact - The introduction of a lower cash price for Repatha highlights the ongoing challenges of affordability in the healthcare system, where access is often dictated by cost [1]